By taking advantage of CEL's ability to inhibit tumor growth and proliferation and resist drug resistance through the modulation of NF‐κB signaling, researchers have coupled docetaxel (DTX) and CEL with lactoferrin to construct a lactoferrin‐dual drug nanoconjugate, which not only significantly improved the solubility, loading capacity, and anti‐breast cancer effect of DTX and CEL, but also effectively overcame the drug resistance challenge of DTX [94]. Here, NFKB1 is linked to breast carcinoma.